Skip to content

Released Nov 1, 2022, before the open

10-Q filed Nov 9, 2022, 38 days after period end · 0000078003-22-000101

Q3 2022 · 10-Q
Revenue$22.64B−5.8% vs Q3 2021−18.4% vs Q2 2022
Net Income$8.61B+5.7% vs Q3 2021−13.1% vs Q2 2022
EPS Diluted$1.51+6.3% vs Q3 2021−12.7% vs Q2 2022
Operating Cash Flowderived$5,974,000,000−44.8%
Free Cash Flowderived$5,133,000,000−49.7%
Margins · derived
Net margin38.0%+4.1 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$22.64B$24.04B$10.28B$12.68B
Net Income$8.61B$8.15B$1.47B$7.68B
EPS Diluted$1.51$1.42$0.26$1.36

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Pfizer Inc · CIK 78003 · Engraved from SEC EDGAR